• Citer

Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial

par Rediti, Mattia ;Venet, David ;Joaquin Garcia, Andrea ;Maetens, Marion M. ;Vincent, Delphine;Majjaj, Samira ;El-abed, Sarra;Di Cosimo, Serena;Ueno, Takayuki;Izquierdo, Miguel;Piccart-Gebhart, Martine ;Pusztai, Lajos;Loi, Sherene ;Salgado, Roberto;Viale, Giuseppe;Rothé, Françoise ;Sotiriou, Christos
Référence Nature communications, 15, 1, 10402
Publication Publié, 2024-12-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial
Auteur:	Rediti, Mattia; Venet, David; Joaquin Garcia, Andrea; Maetens, Marion M.; Vincent, Delphine; Majjaj, Samira; El-abed, Sarra; Di Cosimo, Serena; Ueno, Takayuki; Izquierdo, Miguel; Piccart-Gebhart, Martine; Pusztai, Lajos; Loi, Sherene; Salgado, Roberto; Viale, Giuseppe; Rothé, Françoise; Sotiriou, Christos
Informations sur la publication:	Nature communications, 15, 1, 10402
Statut de publication:	Publié, 2024-12-01
Sujet CREF:	Chimie
	Physique
	Astronomie
	Technologie de l'environnement, contrôle de la pollution
MeSH keywords:	Female
	Humans
	Middle Aged
	Antineoplastic Agents, Immunological -- therapeutic use
	Biomarkers, Tumor -- metabolism -- genetics
	Breast Neoplasms -- genetics -- drug therapy -- pathology -- metabolism
	Gene Expression Profiling
	Gene Expression Regulation, Neoplastic
	Neoplasm Recurrence, Local -- genetics
	Prognosis
	Receptor, ErbB-2 -- metabolism -- genetics
	Trastuzumab -- therapeutic use
	Tumor Microenvironment -- genetics
	Randomized Controlled Trials as Topic
	Clinical Trials, Phase III as Topic
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:2041-1723
	info:doi/10.1038/s41467-024-54621-3
	info:pii/10.1038/s41467-024-54621-3
	info:scp/85211083223
	info:pmid/39613746
	PMC11607438